#USA #Los Angeles #Securities Law #DJS Law Group #Skye Bioscience

Skye Bioscience, Inc. Lawsuit Overview

On December 11, 2025, the DJS Law Group announced a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE) for purported violations of the Securities Exchange Act of 1934. This lawsuit has drawn significant attention among investors, particularly those who acquired shares of Skye within the class period from November 4, 2024, to October 3, 2025.

The core of the lawsuit is a claim that Skye Bioscience knowingly submitted false and misleading statements to the market, leading to substantial investor losses. Specifically, investors allege that the company's product, nimacimab, failed to demonstrate the effectiveness that had been publicly promoted. Consequently, these claims bring into question the integrity of the company's statements during the relevant timeframe, asserting they were not only incorrect but materially misleading.

Key Details of the Case

Class Period and Deadlines

According to the DJS Law Group, interested shareholders are encouraged to get in touch with the firm regarding potential lead plaintiff appointments. However, it is essential to clarify that an appointment as lead plaintiff is not a prerequisite for participating in any recovery efforts related to this case. The deadline for filing claims is set for January 16, 2026.

Allegations Against Skye Bioscience

The complaint indicates that Skye's misleading communications were systematically designed to inflate the market’s perception of its caliber and the prospects for nimacimab. The assertion is that throughout the class period, the company misrepresented the product’s viability, thereby impacting the decision-making process of investors significantly.

Steps for Affected Shareholders

Shareholders who feel they have suffered losses during the specified timeframe are prompted to get in contact with the DJS Law Group. By registering, these stakeholders will benefit from enrollment in a portfolio monitoring service that provides them regular updates throughout the duration of the legal proceedings. There are no associated costs or obligations for shareholders to partake in this class action.

Why DJS Law Group?

DJS Law Group is known for its commitment to robust advocacy and investor recovery. The firm primarily focuses on securities class actions and claims related to corporate governance, claiming to work with some of the most sophisticated clientele in the investment community. Their objective is to ensure that the litigation claims held by their clients are treated with the utmost regard, highlighting their expertise in handling high-stakes legal battles.

DJS Law Group firmly believes that it can provide valuable assistance to investors looking to recover their losses incurred due to the alleged wrongdoing of Skye Bioscience.

Conclusion

The ongoing legal proceedings against Skye Bioscience serve as a critical reminder of the importance of transparency and accountability in the corporate sector. As investors become aware of their rights and seek recourse for any misleading information presented, the implications of this case may extend well beyond the immediate stakeholders involved. Investors who believe they have been negatively impacted should consider their options carefully and seek appropriate legal guidance as the case unfolds.